Abstract
Objective
Non-dipper hypertensives had about three times the risk of atherosclerotic events
than hypertensives whose blood pressure was >10% lower at night compared to daytime
(dippers). Platelet activation and inflammatory response may derive from most atherosclerotic
events. Mean platelet volume (MPV) is a determinant of platelet activation and high
sensitive C-reactive protein (hs-CRP) is the best candidate assay to identify and
monitor the inflammatory response. We aimed to determine whether MPV and hs-CRP levels
are elevated in non-dipper patients compared to dippers and healthy controls. In addition,
we tried to find out if MPV and CRP are related to each other or not in non-dipper
hypertensives.
Method
The total 126 patients study group included 86 patients with hypertension and 40 healthy
subjects (16 male, mean age; 51 ± 4) as control. Ambulatory blood pressure monitoring was performed for all patients.
Hypertensive patients were divided into two groups; 46 dipper patients (18 male, mean
age; 50 ± 9) and 40 non-dipper patients (17 male, mean age; 53 ± 11). Clinical baseline characteristics were similar between groups. We measured mean
platelet volume in a blood sample collected in EDTA tubes and high-sensitive CRP was
measured by using BN2 model nephlometer.
Results
Non-dipper patients demonstrated higher levels of MPV compared to dippers and normotensives
(9.72 ± 0.52 fl vs 9.38 ± 0.33 fl and 8.92 ± 0.42 fl, p < 0.05, respectively). High-sensitive CRP levels were also significantly higher in non-dippers
compared to dippers and normotensives (4.9 ± 1.7 mg/l vs 3.8 ± 1.5 mg/l and 2.7 ± 0.8 mg/l, p < 0.05, respectively). There was significant positive correlation between MPV and CRP
levels (p = 0.002, r = 0.482) in non-dipper hypertensives.
Conclusion
Our results suggest that patients with non-dipping tend to have increased platelet
activation and inflammatory response. Increased platelet activation and inflammatory
response could contribute to increase the atherosclerotic risk in non-dipper patients
compared to dippers.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.Chronobiol Int. 2007; 24: 749-775
- Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension.Circulation. 1990; 81: 528-536
- Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension.J Hypertens. 1992; 10: 875-878
- Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy.Kidney Int. 2004; 65: 621-625
- Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation.Nephron. 1991; 57: 293-298
- Diurnal variation of hemodynamic indices in non-dipper hypertensive patients.Hypertens Res. 2001; 24: 195-201
- Non-dippers are associated with adverse cardiac remodeling and dysfunction.In J Cardiol. 2006; 112: 171-177
- Platelets as predictor of vascular risk: is there a practical index of platelet activity?.Clin Appl Thromb Hemost. 2003; 9: 177-190
- Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function.Br J Haematol. 1982; 50: 509-519
- Platelet size in myocardial infarction.Br Med J. 1983; 287: 449-451
- Changes in platelet size and count in unstable angina pectoris compared to stable or non-cardiac chest pain.Eur Heart J. 1998; 19: 80-84
- Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol.Int J Cardiol. 2007; 116: 206-211
- PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of CVD.Stroke. 2004; 35: 622-626
- Mean platelet volume as an indicator of platelet activation: methodological issues.Platelets. 2002; 13: 301-306
- Influence of platelet size on outcome after myocardial infarction.Lancet. 1991; 338: 1409-1411
- The effect of mean platelet volume on the short term prognosis of acute myocardial infarction.Res Esp Cardiol. 1998; 51: 816-822
- Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association.Circulation. 2003; 107: 499-511
- Clinical application of C-reactive protein for cardiovascular disease detection and preventation.Circulation. 2003; 107: 363-369
- The seventh report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC 7).J Am Med Assoc. 2003; 289: 2560-2572
- Blood pressure as a cardiovascular risk factor: prevention and treatment.JAMA. 1996; 275: 1571-1576
- Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension.Circulation. 2001; 103: 2579-2584
- Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subject.J Am Coll Cardiol. 2002; 39: 878-885
- The biological significance of platelet volume; its relationship to bleeding time, TXA2 production and megakaryocyte nuclear DNA concentration.Thromb Res. 1983; 32: 443-460
- Influence of aspirin on platelet count and volume in human.Acta Haematol. 1999; 101: 140-144
- Platelet indexes in relation to target organ damage in high risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).J Am Coll Cardiol. 2004; 44: 415-422
- Thrombocytopenia and macrothrombocytosis in gestational hypertension.Br J Obstet Gynaecol. 1981; 88: 1115-1119
- The mean platelet volume in patients with essential and white coat hypertension.Platelets. 2005; 16: 435-438
- Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease.Thromb Res. 2007; 120: 245-250
- Inflammation and atherosclerosis.Circulation. 2002; 105: 1135
- Widespread coronary inflammation in unstable angina.N Engl J Med. 2002; 347: 5-12
- C-reactive protein: a new risk assessment tool for cardiovascular disease.J Am Osteopath Assoc. 2005; 105: 409-416
- Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension.J Hum Hypertens. 2008; 22: 501-508
- Atherosclerosis—an inflammatory disease.N Engl J Med. 1999; 340: 115-126
- RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.Circulation. 2001; 103: 1772-1777
- Interleukin-1 as a factor in occlusive vascular disease.Am J Clin Pathol. 1992; 97: 8-13
- Platelet glycoprotein Ib is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18).J Exp Med. 2000; 192: 193-204
- Mean platelet volume measurement, EDTA or citrate?.Hematology. 2006; 11: 317-319
- Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system.Clin Chem. 2002; 48: 891-899
Article info
Publication history
Published online: September 27, 2009
Accepted:
September 4,
2009
Received in revised form:
September 3,
2009
Received:
May 14,
2009
Identification
Copyright
© 2009 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
